JP2024524180A5 - - Google Patents

Info

Publication number
JP2024524180A5
JP2024524180A5 JP2023578701A JP2023578701A JP2024524180A5 JP 2024524180 A5 JP2024524180 A5 JP 2024524180A5 JP 2023578701 A JP2023578701 A JP 2023578701A JP 2023578701 A JP2023578701 A JP 2023578701A JP 2024524180 A5 JP2024524180 A5 JP 2024524180A5
Authority
JP
Japan
Prior art keywords
once
weekly dose
ggg
tri
receptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524180A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034437 external-priority patent/WO2022271767A1/en
Publication of JP2024524180A publication Critical patent/JP2024524180A/ja
Publication of JP2024524180A5 publication Critical patent/JP2024524180A5/ja
Pending legal-status Critical Current

Links

JP2023578701A 2021-06-23 2022-06-22 インクレチン類似体の使用方法及びインクレチン類似体を含む組成物 Pending JP2024524180A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213956P 2021-06-23 2021-06-23
US63/213,956 2021-06-23
PCT/US2022/034437 WO2022271767A1 (en) 2021-06-23 2022-06-22 An incretin analog for use in glycemic control and weight management

Publications (2)

Publication Number Publication Date
JP2024524180A JP2024524180A (ja) 2024-07-05
JP2024524180A5 true JP2024524180A5 (enExample) 2024-12-02

Family

ID=82608370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578701A Pending JP2024524180A (ja) 2021-06-23 2022-06-22 インクレチン類似体の使用方法及びインクレチン類似体を含む組成物

Country Status (11)

Country Link
US (3) US12496329B2 (enExample)
EP (1) EP4358994A1 (enExample)
JP (1) JP2024524180A (enExample)
KR (1) KR20240024936A (enExample)
CN (1) CN117915939A (enExample)
AU (2) AU2022298662B2 (enExample)
BR (1) BR112023027321A2 (enExample)
CA (1) CA3223313A1 (enExample)
IL (1) IL309604A (enExample)
MX (3) MX2024000213A (enExample)
WO (1) WO2022271767A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102812908B1 (ko) * 2019-08-19 2025-05-28 일라이 릴리 앤드 캄파니 인크레틴 유사체의 제조 방법
CN117320740A (zh) * 2021-02-17 2023-12-29 伊莱利利公司 Gip/glp1双重激动剂治疗方法
WO2026037397A1 (zh) * 2024-08-16 2026-02-19 江苏恒瑞医药股份有限公司 Glp-1类似物的医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2548275T3 (es) 2010-03-01 2015-10-15 Eli Lilly And Company Dispositivo de inyección automático con mecanismo de retardo que incluye un elemento de empuje de funcionamiento doble
KR102589234B1 (ko) 2017-11-21 2023-10-16 일라이 릴리 앤드 캄파니 둘라글루티드를 함유하는 조성물 및 사용 방법
AR113486A1 (es) 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
TW202140058A (zh) 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途

Similar Documents

Publication Publication Date Title
JP2024524180A5 (enExample)
Aroda et al. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes
Wysham et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)
Ramachandran et al. Current status of diabetes in India and need for novel therapeutic agents
Su et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials
Sanford Dulaglutide: first global approval
Barnett et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy
Smith et al. Dulaglutide (Trulicity): the third once-weekly GLP-1 agonist
Scott Linagliptin: in type 2 diabetes mellitus
Jackson et al. Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes
Hirsch et al. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST® T1)
Yale et al. Use of once‐weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE C anada multicentre, prospective, observational study
Yoon et al. Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes
Blair et al. Albiglutide: a review of its use in patients with type 2 diabetes mellitus
Brunton Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens
Lingvay et al. Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial
Sisson Liraglutide: clinical pharmacology and considerations for therapy
Tomlinson et al. An overview of alogliptin+ pioglitazone for the treatment of type 2 diabetes
Davies et al. Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan‐O randomized trial
Greig et al. Insulin degludec/liraglutide: a review in type 2 diabetes
Bain The clinical development program of lixisenatide: a once-daily glucagon-like peptide-1 receptor agonist
Aroda et al. High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight or obesity: a randomized, placebo-controlled, phase 2 trial
Kalra et al. Injectable coformulations in diabetology
Handelsman et al. Glycemic efficacy, weight effects, and safety of once-weekly glucagon-like peptide-1 receptor agonists
JP2024524180A (ja) インクレチン類似体の使用方法及びインクレチン類似体を含む組成物